Infliximab (Remicade) Plus Intravenous Immunoglobulin (IVIG) for the Primary Treatment of Patients With Acute Kawasaki Disease

Trial Profile

Infliximab (Remicade) Plus Intravenous Immunoglobulin (IVIG) for the Primary Treatment of Patients With Acute Kawasaki Disease

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Dec 2014

At a glance

  • Drugs Infliximab (Primary)
  • Indications Mucocutaneous lymph node syndrome
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Apr 2014 Results published in the Lancet (online).
    • 14 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top